Uncategorized - April 16, 2020
A Health Catapult Centre is taking shape in Norway
Three Norwegian health innovation clusters will collaborate on forming a concept for the first Norwegian Health Catapult Centre, with the aim to support innovative SMEs. Siva, a governmental enterprise facilitating a national infrastructure for innovation, has selected Oslo Cancer Cluster Incubator, Norway Health Tech and Norwegian Smart Care Cluster to proceed to the next round […]
Past events - September 25, 2019
Norway for Life Science at NLSDays 2019
The biggest key players from the life science industry in Norway came together in Malmö with a common goal: to promote Norwegian life science and build Nordic collaboration. Sofia Lindén, Communications adviser at Oslo Cancer Cluster, has summarized the NLSDays 2019 and the Norwegian participation. The life science industry in Norway is booming and collaboration […]
Uncategorized - May 10, 2019
NOK 4.5 million invested in Norwegian cancer research
Radforsk, the Radium Hospital Research Foundation, is awarding several NOK 4.5 million to new research that fights cancer with light, reports Elisabeth Kirkeng Andersen, Oslo Cancer Cluster. Radforsk is an evergreen investor focusing on companies that develop cancer treatment. Since its inception in 1986, Radforsk has allocated NOK 200 million of its profit back into cancer […]
Column - July 4, 2018
Size matters – Nordic collaboration in oncology – now
The biopharmaceutical industry is in a frenzy to develop innovative drugs for cancer and no wonder, when the market size is estimated to be over 800 BNOK in 2020, the population worldwide is getting older and the incidence and prevalence of cancer is increasing. Hence – the need for better treatments is increasing exponentially. Both […]
Biotech Business - May 30, 2017
Co-cluster project at OCC stimulates IT-Biotech collaborations
Oslo Cancer Cluster (OCC) is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. The project aims to utilize novel IT-solutions to accelerate drug development in biotech companies. “I know of companies who still manage their clinical trial studies using Excel. This is not a good idea. An Excel sheet may only hold […]
Clinical Trials - May 10, 2017
Roche’s lung cancer drug receives approval by the Norwegian Medicines Agency
Clinical data from a phase III study of the lung cancer medicine, named Alecensa, also shows significant approved survival for lung cancer patients. The specific form of lung cancer this drugmis approved for, is called anaplastic lymfomkinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). In Norway lung cancer affects about 3 035 people per […]
